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LETTERS TO THE EDITOR
 To the Editor: Th e pathogenesis of Crohn ’ s 
disease (CD) is not known: the currently 
accepted hypothesis is that genetic suscep-
tibility and environmental factors coop-
erate to trigger the chronic infl ammation 
typical of the disease. Recent evidence 
implicating the gut microbiome in CD 
development has generated interest in its 
characterization ( 1 ). Previous studies have 
shown that bacterial diversity is reduced 
in CD patients, that bacterial populations 
in CD patients diff er in relation to pheno-
type, and that the microbial composition 
diff ers signifi cantly between infl amed and 
non-infl amed mucosal areas ( 2 ). 
 Nutritional therapy is eff ective in pedi-
atric CD; it induces remission of mucosal 
infl ammatory reactions and exerts a ben-
efi cial eff ect on the child ’ s nutritional sta-
tus and growth ( 3 ). It has been suggested 
that nutritional therapy may modify the 
fecal microfl ora in CD children ( 4 ). In an 
attempt to address this hypothesis, we char-
acterized the entire gut mucosal microbi-
ome in a child with CD at diagnosis and 
aft er nutritional therapy, and in a sex- and 
age-matched subject not aff ected by CD. 
 Th is 14-year-old boy was diagnosed with 
active CD (Pediatric Crohn ’ s Disease Activ-
ity Index, PCDAI  =  50). Aft er colonoscopy, 
he underwent nutritional therapy consisting 
of a daily powder constituted by proteins, 
microbiome composition in these three 
ileum samples. A specifi c amplicon was 
designed to cover the V4 – V6 variable 
regions of the bacterial 16S rRNA genes 
and amplifi ed using hybrid-tagged primers. 
Ultra-deep amplicon sequencing was per-
formed on the 454 Genome Sequencer 
FLX instrument (Roche Life Science, 
Branford, CT). Data were analyzed using 
the QIIME community analysis pipeline 
( 5 ). High-quality fi ltered sequences were 
used to identify the operational taxonomic 
antioxidants, and anti-infl ammatory fats 
(Alicalm formula, Nutricia Advanced 
Medical Nutrition) for 8 weeks. Aft er this 
time, a clinical re-evaluation revealed dis-
ease remission (PCDAI  =  0). Endoscopic 
ileum mucosal samples at diagnosis and 
aft er therapy were collected for DNA 
extraction. An ileum tissue sample was 
obtained from a 15-year-old boy with a 
gut polyp and without family history of 
CD. We used a 16S rRNA next-generation 
sequencing strategy to investigate the gut 
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 Figure 1 .  Composition of the ileum microbiome characterized in the control subject and in the 
Crohn ’ s disease (CD) patient before therapy (patient-BT) and after therapy (patient-AT) by next-
generation sequencing of the 16S rRNAs. ( a ) Phylum-level classifi cation shows the reduction of 
 Bacteroidetes and the signifi cant prevalence of  Proteobacteria in the patient-BT vs. the control and 
the patient-AT. ( b ) The heatmap table highlights in brownish red the most signifi cant alterations in the 
bacterial composition of gut microbiome detected in the CD patient-BT; the numerical fi gures indicate 
the number of bacterial families sequenced in each patient. 
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units (OTUs): 705, 1,328, and 2,171 OTUs 
were obtained in the patient before and 
aft er therapy, and in the control subject, 
respectively. On the basis of the taxonomic 
assignment of the OTUs, we characterized 
the ileum microbiome of our samples at fi ve 
phylogenetic levels (from phylum to genus). 
As shown in  Figure 1 ,  Proteobacteria 
were more abundant, and  Bacteroidetes less 
abundant, in our CD patient before ther-
apy than in the control. Interestingly, the 
composition of the ileum microbiome in 
the patient aft er therapy was virtually the 
same as in the control. Moreover, our data 
support the reduced bacterial diversity of 
the CD microbiome. In fact, the Shannon 
Diversity Index Score was signifi cantly 
lower ( P  <  0.05) in our CD patient before 
therapy than aft er therapy and also when 
compared with the control ( Figure 2 ). 
 Although our fi ndings were obtained 
in one case – control study, and therefore 
may be considered preliminary, they 
strongly suggest that nutritional therapy 
can improve the infl ammatory status of 
CD by restoring the composition of the 
mucosal microbiome. Th is case of CD 
gut microbiome dysbiosis that responded 
to nutritional therapy can be considered 
proof-of-concept to evaluate a similar 
approach in other pediatric clinical 
laboratories and may serve to prompt mul-
ticenter studies and possible clinical trials. 
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 Figure 2 .  The mean Shannon Diversity Index Score. Values were signifi cantly lower before therapy 
(patient-before therapy (patient-BT)) compared with values obtained after treatment (patient after 
therapy (patient-AT)) and with values obtained in the control subject ( * P  <  0.05). 
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